Mirati is once again the center of buyout rumors, and a rival's adcomm provides a boost
Mirati Therapeutics is once again attracting buyout interest, this time allegedly from Sanofi, according to a report from Bloomberg on Thursday. The biotech’s shares $MRTX surged by roughly 45% in response.
It’s far from the first time Mirati has emerged as a potential takeover target. Merck reportedly considered acquiring the company back in 2021, per a report from BioSpace at the time, as it looked to stave off the upcoming Keytruda patent cliff. And Bloomberg previously reported last year that unnamed Big Pharma companies were looking into a buyout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
